SOURCE: King & Spalding

King & Spalding

July 05, 2011 15:36 ET

King & Spalding Advises Immucor in Its $1.97 Billion Sale to TPG Capital

NORCROSS, GA--(Marketwire - Jul 5, 2011) - King & Spalding advised Immucor, Inc., a global leader in providing automated instrument-reagent systems to the blood transfusion industry, in its definitive agreement to be acquired by investment funds managed by TPG Capital in a transaction with a fully diluted equity value of $1.973 billion.

Under the terms of the agreement, Immucor shareholders will receive $27.00 in cash for each share of Immucor common stock they own. The transaction is expected to close in the second half of 2011.

Additional details about this transaction can be found here:

The King & Spalding legal team involved in the transaction was led by M&A partners C. William Baxley and John D. Capers, Jr., and consisted of the following lawyers:

Mergers and Acquisitions
Justin M. King (associate, Atlanta)
Matthew S. McCoy (associate, Atlanta)
Spencer A. Stockdale (associate, Atlanta)

Alan J. Prince (partner, Atlanta)
Christopher M. Bugay (associate, Atlanta)
Adam J. Humphreys (associate, Atlanta)
Robert J. Leclerc (associate, New York)

Employee Benefits
Eleanor Banister (partner, Atlanta)

Ram Burshtine (partner, New York)

L. Wayne Pressgrove (partner, Atlanta)
Matthew R. Servies (associate, Atlanta)

Les A. Oakes (partner, Atlanta)

Kevin R. Sullivan (partner, Washington)
Brian R. Meiners (associate, Washington)

About King & Spalding
Celebrating 125 years of service, King & Spalding is an international law firm with more than 800 lawyers in Abu Dhabi, Atlanta, Austin, Charlotte, Dubai, Frankfurt, Geneva, Houston, London, Moscow, New York, Paris, Riyadh (affiliated office), San Francisco, Silicon Valley, Singapore and Washington, D.C. The firm represents half of the Fortune 100 and, according to a Corporate Counsel survey in August 2009, ranks fifth in its total number of representations of those companies. For additional information, visit

Contact Information